glp-1 patent Medicines Pool Executive Director Charles Gore tells Devex that one of his priorities in his last year on the job is to get a license for therapies. But he admits June 2024 Patent Highlights: GLP-1R

124 GLP-1, by activating its receptor, increases insulin secretion and reduces glucagon secretion, thereby lowering blood sugar levels

PPG neurons in the nucleus of the solitary tract modulate heart rate but do not mediate GLP-1 receptor agonist-induced tachycardia in mice

Clinicians will also evaluate a patient for medical conditions that might make weight loss more challenging, such as perimenopause or hypothyroidism, which is underactive thyroid

This evolving landscape highlights the growing importance of innovation and patent strategies in shaping the future of weight loss and obesity treatments

Prescribing Information: Victoza (liraglutide) injection